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(12 neonates and 14 symptomatic) patients with infantile Krabbe
disease were treated with unrelated donor umbilical cord blood
transplantation after myeloablative chemotherapy. Donors with
higher galactocerebrosidase levels were selected. Engraftment, sur-
vival, and neurodevelopmental function were evaluated longitudi-
nally for 1 to 7 years. The probabilities of donor cell engraftment
and overall survival were 100% in the neonates and 43% in the
symptomatic group. Surviving patients demonstrated durable en-
graftment of donor-derived hematopoietic cells with restoration of
normal blood galactocerebrosidase levels. The symptomatic group
of patients experienced minimal improvement after transplant. In
contrast, the neonates demonstrated progressive central myelina-
tion and improvement in nerve conduction studies with increasing
age. All neonatally transplanted patients continue to gain develop-
mental skills with most having age appropriate cognitive function
and receptive language but slower gains in expressive language and
gross motor function. Conclusions are (1) unrelated umbilical cord
blood transplantation after myeloablative chemotherapy is beneﬁ-
cial in neonates with infantile Krabbe Disease favorably altering
the natural history of the disease, especially neurodevelopmental
function and (2) previously non-traditional stem cell transplant
candidates receive beneﬁt from early intervention with cord blood
transplantation.
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A PICTURE IS WORTH A THOUSAND WORDS: DIGITAL PHOTOGRAPHS
ENHANCE AMBULATORY TELEPHONE TRIAGE
Taylor, J.M., Ford, R.E., Schmidt, E.A. Memorial Sloan Kettering
Cancer Center, New York, NY.
Triaging a patient’s symptoms over the telephone is challenging,
even for the seasoned practitioner. Hematopoietic stem cell trans-
plant patients receiving complicated treatment regimens require
comprehensive assessments and timely interventions to manage
symptoms from home. Factors including type of transplant, day
post transplant, presence of a central line, and status of immune
recovery are all considered in assessing the symptom(s) a patient
may report from home. Distance from the hospital, ability to get to
the hospital, and patient reliability must also be considered. Al-
though e-mail communication with patients does not replace direct
telephone contact, digital photographs sent via e-mail can be ex-
tremely beneﬁcial in supporting a telephone assessment. For ex-
ample, patients may struggle trying to verbally describe skin and
oral changes in the setting of graft-versus-host disease. For patients
with the capability to e-mail a digital photograph, a picture can
literally be worth a thousand words. The picture may help illustrate
a new problem, differentiate a change, deﬁne the extent of a
problem, and/or help eliminate the subjectivity of the patient. It
can be shared with colleagues whose opinion is sought, and it may
help with determination of a treatment strategy. The photograph
can potentially establish the urgency of a problem and whether it
can be managed without the person having to leave home. One less
trip to the hospital can enhance a patient’s quality of life in terms
of time, comfort, convenience, and cost. For the practitioner as
well, this tool can be cost saving as well as an efﬁcient use of time.
Although e-mail communication should never replace verbal as-
sessment of symptoms, we recognize situations where an e-mail
with a digital photo attachment is beneﬁcial, and we should em-
brace it as a valuable tool for enhancing patient care.
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STOP FOR SAFETY: REDUCING FALLS IN BMT
Kulma, A., Meyers, A.L., Johnston, P.A. M. D. Anderson Cancer
Center, Houston, TX.
Within M. D. Anderson Cancer Center, the Blood and Marrow
Transplant (BMT) center is the largest transplant center in the
world, performing an estimated 600 transplants per year. Between
September of 2003 and July of 2004, M. D. Anderson’s inpatient
center experienced 335 patient falls. Sixty-four of these falls oc-
curred on the BMT ﬂoor. With the increasing trend of the fall
incidence rate on the BMT unit, a multi-disciplinary Falls
Taskforce Committee was created to address this pertinent
issue. Based on research performed by the committee, it was
determined that a tool would be created utilizing variance report
data, research found in the literature review, and tools present in
the literature. The ﬁrst purpose of the project was the creation
of a new fall risk tool. This tool was created to correctly identify
and classify the risk factors speciﬁc to the BMT patient. Based
on the calculated score from the BMT tool, the patient was
placed into one of three risk categories that encompassed level-
speciﬁc interventions. This included low (green), medium (yel-
low), and high (red) risk categories. The second purpose of this
project was to increase the nursing staff’s knowledge and aware-
ness of the identiﬁed risk factors and to educate them on the use
of the newly created fall assessment tool. This purpose aided in
the correct assessment of the high risk patient. A pre-test and a
post-test were given to evaluate the success of the 30 minute
in-service. The clinical application of the risk assessment tool
was evaluated through the utilization of an audit tool checklist.
Weekly chart audits were performed in order to determine
proper implementation and staff compliance of the new fall
prevention program. Using a repeated measures t test, there was
a substantial increase in percentage of questions answered cor-
rectly between the pre-test and the post-test. Overall compli-
ance rate for the project implementation was 75.3%. A success-
ful fall prevention program aids in the responsibility of keeping
patients safe and attempts to eradicate unnecessary complica-
tions, while promoting health restoration after the bone marrow
transplant process. In doing so, it aids the patient and the health
care team in reaching the ultimate goal of making cancer his-
tory.
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THE AMAZING RACE—TO MBL HELL AND BACK. AN OUTBREAK OF
METALLO-BETA-LACTAMASE PRODUCING PSEUDOMONAS AERUGI-
NOSA (MBL-Psa) ON A BONE MARROW TRANSPLANT UNIT
Pauling-Shepard, K.L.1, Ward, L.P.1, Bouchard, M.K.1,
Leavitt, J.M.1, Houshmand, S.L.2, Russell, J.A.2, Louie, T.J.1 1.
Foothills Medical Centre, Calgary Health Region, Calgary, AB, Canada;
2. Tom Baker Cancer Centre, Alberta Cancer Board, Calgary, AB,
Canada.
Introduction: Between June 17, 2003 and November 3, 2004
the BMT ward experienced a clonal MBL-Psa outbreak involv-
ing 28 patients, 16 of whom developed infection (bacteremia 
12, pneumonia  2, UTI  1, CVC access site  1) and 12
patients developed asymptomatic rectal colonization. Coloniza-
tion was observed both before and after infection. Patients
included allogeneic BMT (14), autologous BMT (8), and
haematology/other oncology (6). The outbreak began immedi-
ately after a 3 month waterborne outbreak involving the same
strain in the main ICU, which was arrested by eliminating faucet
aerator contamination in 4 automatic handwashing sinks. The
BMT unit outbreak presented as sporadic cases of MBL-Psa
infection occurring every 4 to 7 weeks (Table1). Results: MBL
carriage was reduced but not eliminated by outbreak control
measures. Tap/faucet/sink contamination was documented sev-
eral times, however, correction did not stop the outbreak. Ul-
timately, the outbreak was traced to contamination of a patient
room sink shut off-valve. Following correction, 30 weeks of
surveillance showed no MBL-Psa activity. Discussion: Pro-
gram-wide inpatient and outpatient teamwork, in collaboration
with Infection Prevention and Control, was integral in the
control of MBL-Psa. Persistent epidemiologic investigations
and detailed water cultures arrested this outbreak. Low level
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water contamination from a single source can result in wide-
spread cases.
Table 1. Outbreak Investigation
Process/
practice
reviews
Changes
DescriptionY N
Infection
Control
Surveillance
 Performed point prevalence
surveys (rectal cultures) and/or
roommate contact tracing after
each MBL-Psa cluster/case;
established weekly rectal
surveillance (week 24 of
outbreak)
Hand hygiene  Reviewed hand hygiene practices;
increased usage of alcohol hand
rub; recommended against
artificial nails/nail extenders
Central line
care
 Relocated CVC flush processes
away from handwashing sink
Housekeeping  Enhanced unit environmental
cleaning; intermittently attempted
sink drain decontamination (1:
1000 ppm sodium hypochlorite);
discontinued use of contaminated
spray cleaner/deodorizer
Equipment
cleaning
 Reviewed and reorganized
processes
Education  Reviewed Standard Practice and
isolation precautions with all
staff; provided ongoing
education/outbreak feedback to
stakeholders
Patient Care  Restricted routine use of
Carbapenems for febrile
neutropenia; discontinued use of
Ciprofloxacin prophylaxis;
discontinued off-service
admissions; initiated private room
accomodation for all
BMT/hematology/ febrile
neutropenic patients; reinforced
sterile water for nebulizers;
discontinued ambient air
nebulizers for patients with
mucositis; continued contact
isolation for presumptive/
confirmed cases
Environmental
Culturing and
Maintenance
 Performed repeated environmental
and water cultures; removed
faucet aerators and sink stoppers;
replaced medication room/staff
washroom sinks, tub, all sink
grout, and one cold water shut-off
valve
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TEMPORAL THERMOMETER USE FOR MONITORING BONE MARROW
TRANSPLANTATION PATIENTS: COMPARISON WITH ORAL THERMOM-
ETER
Akins, P.A., Mobley, S.A., Scott, D., Rybicki, L. Cleveland Clinic
Foundation, Cleveland, OH.
Monitoring Bone Marrow Transplant (BMT) patients for fever is
essential assessment data for early recognition of infection. The
current method of monitoring is oral thermometry (OT). How-
ever, a signiﬁcant number of BMT patients experience oral mu-
cositis, making fever monitoring uncomfortable. Mucositis pain
may prevent patients from being able to correctly place the ther-
mometer, affecting the accuracy of the readings. The temporal
thermometer (TT) is an alternative method of assessment. The
purpose of this project is to explore the differences between TT
and OT monitoring in BMT patients and to assess patient comfort
associated with each method. BMT patients receive a myeloblative
chemotherapy regimen prior to transplant. Neutropenia occurs
within 2 to 3 weeks of therapy and is indicated when the neutrophil
count falls below 1000/mm3. Infection is the major cause of mor-
bidity and mortality among BMT patients. During the ﬁrst 3 to 4
weeks following transplantation, most patients will develop a fever.
In 30 to 40%, blood cultures show bacterial pathogens. A fever in
a neutropenic patient is deﬁned as a temperature 	38.0° C. Alter-
native methods of monitoring fever include pulmonary artery mea-
surement, rectal thermometers, tympanic thermometers, and tem-
poral thermometers. The use of pulmonary artery and rectal
thermometry are contraindicated, as any invasive procedure places
a pancytopenic patient at added risk for infection. The tympanic
thermometer readings can vary, depending on instrument place-
ment, making it unreliable for monitoring fever in BMT patients.
To date no studies have examined the use of TT for monitoring
fever in immunocompromised BMT patients. This is a prospective
exploratory study examining the differences between OT and TT
monitoring in BMT patients. Data will be collected 4 times a day
for 4 days from a convenience sample of BMT patients from M50.
Patients will receive usual routine fever monitoring using OT
method and simultaneously will have their temperature monitored
using the TT method. To standardize assessment of mucositis, the
Oral Mucosa Assessment Scale (OMAS) will be completed daily on
each patient. To assess discomfort, the RN or PCNA will ask the
patient to rate the level of comfort-discomfort related to place-
ment, using a 0 to 10 verbal rating scale. This proposal is still in a
data collection phase, and the ﬁndings may direct change for future
practice to beneﬁt future patients.
452
NURSING CARE OF THE GRANULOCYTE DONOR FOR PEDIATRIC STEM
CELL TRANSPLANT PATIENTS
Stanton, T.J., Marconi, A.L., Allison, J., Kurtzberg, J. Duke Univer-
sity Hospital, Durham, NC.
Infection continues to be the leading cause of morbidity and
mortality in patients with severe and sustained neutropenia deﬁned
as an Absolute Neutrophil Count of 500/uL. Cesaro et. al (2003)
concludes that “granulocyte transfusion therapy is potentially use-
ful when the severity of the infection and the host’s immunodeﬁ-
ciency make any other antimicrobial therapy ineffectual.” The
Duke Pediatric Blood and Marrow Transplant program uses gran-
ulocyte transfusion therapy for persistently neutropenic patients
with severe infections and for patients who must undergo a second
bone marrow transplant. Donors are required to go through blood
donor questionnaires and blood testing to ensure the safety of both
the donor and the recipient per FDA donor regulations effective
5/25/2005. When possible, a CMV negative donor is selected.
Once a donor is selected (usually a relative of the patient) a double
lumen pheresis catheter is placed for the duration of the donation.
The donor is primed with G-CSF 10 mcg/kg twice weekly. Gran-
ulocytes are harvested by pheresis 14 to 16 hours post G-CSF
dosing, irradiated, divided into 3 doses, and administered IV to the
patient daily  3. With 2 pheresis per week, the recipient receives
granulocytes 6/7 days. Nurse coordinators and staff nurses on the
inpatient transplant unit collaborate to provide the majority of care
and education to the granulocyte donors in order to provide con-
sistency of care for families. The transplant patient’s nurse is
responsible for monitoring and maintaining the pheresis catheter
and for administering G-CSF by injection to the donor. The nurse
must also educate the donor about possible side effects of G-CSF
therapy and granulocyte donation as well as ways to prevent these
side effects. The purpose of this poster will be to (1) educate the
learner about the nurse’s responsibility in caring for the granulo-
cyte donor; (2) describe the standard operating procedure for daily
Transplant Nursing
155BB&MT
